IMRX
Immuneering CorporationNASDAQHealthcare$5.45+2.25%ClosedMarket Cap: $197.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.09
P/S
0.00
EV/EBITDA
-1.21
DCF Value
$2.80
FCF Yield
-23.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-43.3%
ROA
-24.2%
ROIC
-26.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-13.8M | $-11.6M | $-0.18 | — |
| FY 2025 | $0.00 | -Infinity% | $-59.4M | $-56.0M | $-1.27 | — |
| Q3 2025 | $0.00 | -Infinity% | $-15.4M | $-15.0M | $-0.38 | — |
| Q2 2025 | $0.00 | NaN% | $-14.8M | $-14.4M | $-0.40 | — |
| Q1 2025 | $0.00 | NaN% | $-15.5M | $-15.0M | $-0.42 | — |
| Q4 2024 | $0.00 | -Infinity% | $-18.6M | $-18.1M | $-0.58 | — |
| FY 2024 | $0.00 | NaN% | $-64.1M | $-61.0M | $-2.04 | — |
| Q3 2024 | $0.00 | NaN% | $-15.3M | $-14.6M | $-0.49 | — |
| Q2 2024 | $0.00 | NaN% | $-14.9M | $-14.1M | $-0.47 | — |
| Q1 2024 | $0.00 | NaN% | $-15.3M | $-14.3M | $-0.49 | — |
| Q4 2023 | $0.00 | -Infinity% | $-16.3M | $-15.1M | $-0.52 | — |
| FY 2023 | $0.00 | NaN% | $-58.4M | $-53.5M | $-1.88 | — |